The REACH Study (MTN-034) | Microbicide Trials Network

REACH (Reversing the Epidemic in Africa with Choices in HIV prevention), or MTN-034, is a Phase IIa study that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women, who are among the most vulnerable to HIV in sub-Saharan Africa. Specifically, REACH will evaluate how adolescent girls and young women use the monthly dapivirine vaginal ring and Truvada^® as daily pre-exposure prophylaxis (PrEP) and their preferences for either or both approaches. The study will also collect much needed information on the safety of these approaches in young women.